These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31805108)

  • 21. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.
    Gustafsen C; Olsen D; Vilstrup J; Lund S; Reinhardt A; Wellner N; Larsen T; Andersen CBF; Weyer K; Li JP; Seeberger PH; Thirup S; Madsen P; Glerup S
    Nat Commun; 2017 Sep; 8(1):503. PubMed ID: 28894089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of Organo-Peptides As Bipartite PCSK9 Antagonists.
    Burdick DJ; Skelton NJ; Ultsch M; Beresini MH; Eigenbrot C; Li W; Zhang Y; Nguyen H; Kong-Beltran M; Quinn JG; Kirchhofer D
    ACS Chem Biol; 2020 Feb; 15(2):425-436. PubMed ID: 31962046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First Food-Derived Peptide Inhibitor of the Protein-Protein Interaction between Gain-of-Function PCSK9
    Grazioso G; Bollati C; Sgrignani J; Arnoldi A; Lammi C
    J Agric Food Chem; 2018 Oct; 66(40):10552-10557. PubMed ID: 30226051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of (2-(4-Substituted phenyl)quinolin-4-yl)(4-isopropylpiperazin-1-yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
    Wang X; Zhang L; Wang X; Zhu D; Xu G; Li H; Zhang L
    ChemMedChem; 2024 Jan; 19(2):e202300498. PubMed ID: 38054966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor.
    Garvie CW; Fraley CV; Elowe NH; Culyba EK; Lemke CT; Hubbard BK; Kaushik VK; Daniels DS
    Protein Sci; 2016 Nov; 25(11):2018-2027. PubMed ID: 27534510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
    Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
    Winston-McPherson GN; Xie H; Yang K; Li X; Shu D; Tang W
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2345-2348. PubMed ID: 31227343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Silico Insights into Protein-protein Interaction Disruptive Mutations in the PCSK9-LDLR complex.
    Martin WR; Lightstone FC; Cheng F
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy.
    Lavecchia A; Cerchia C
    Future Med Chem; 2019 Mar; 11(5):423-441. PubMed ID: 30892945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9.
    Sánchez-Hernández RM; Di Taranto MD; Benito-Vicente A; Uribe KB; Lamiquiz-Moneo I; Larrea-Sebal A; Jebari S; Galicia-Garcia U; Nóvoa FJ; Boronat M; Wägner AM; Civeira F; Martín C; Fortunato G
    Atherosclerosis; 2019 Oct; 289():162-172. PubMed ID: 31518966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.